GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Price-to-Owner-Earnings

Lattice Biologics (Lattice Biologics) Price-to-Owner-Earnings : (As of May. 06, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Price-to-Owner-Earnings?

As of today (2024-05-06), Lattice Biologics's share price is $0.0001. Lattice Biologics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Lattice Biologics's Price-to-Owner-Earnings or its related term are showing as below:


LBLTF's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.425
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-06), Lattice Biologics's share price is $0.0001. Lattice Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.01. Therefore, Lattice Biologics's PE Ratio for today is At Loss.

As of today (2024-05-06), Lattice Biologics's share price is $0.0001. Lattice Biologics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.01. Therefore, Lattice Biologics's PE Ratio without NRI for today is At Loss.


Lattice Biologics Price-to-Owner-Earnings Historical Data

The historical data trend for Lattice Biologics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Price-to-Owner-Earnings Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.00 - - -

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lattice Biologics's Price-to-Owner-Earnings

For the Medical Devices subindustry, Lattice Biologics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Price-to-Owner-Earnings falls into.



Lattice Biologics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lattice Biologics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0001/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lattice Biologics  (OTCPK:LBLTF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lattice Biologics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines